Literature DB >> 17045203

AKT and cancer--is it all mTOR?

Neal Rosen1, Qing-Bai She.   

Abstract

AKT, a key regulator of cell proliferation and survival, is commonly dysregulated in human cancers. Activated AKT kinase is oncogenic and required for tumorigenesis in PTEN-deficient animals. However, the importance of AKT in mediating transformation by other oncogenes and which of its targets are necessary for this process are poorly understood. In this issue of Cancer Cell, Skeen et al. show that AKT is required for transformation by mutant H-Ras and for experimental skin carcinogenesis. Moreover, the effects of AKT are mediated predominantly or solely via mTORC1. This suggests that AKT or mTOR inhibitors will be useful treatments for many cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045203     DOI: 10.1016/j.ccr.2006.10.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  24 in total

1.  Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.

Authors:  Kangdong Liu; Chanmi Park; Shengqing Li; Ki Won Lee; Haidan Liu; Long He; Nak Kyun Soung; Jong Seog Ahn; Ann M Bode; Ziming Dong; Bo Yeon Kim; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-04-24       Impact factor: 4.944

2.  Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.

Authors:  Yu Gao; Ronald B Gartenhaus; Rena G Lapidus; Arif Hussain; Yanting Zhang; Xinghuan Wang; Han C Dan
Journal:  Mol Cancer Res       Date:  2015-09-15       Impact factor: 5.852

3.  The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.

Authors:  Oscar Tapia; Ismael Riquelme; Pamela Leal; Alejandra Sandoval; Susana Aedo; Helga Weber; Pablo Letelier; Enrique Bellolio; Miguel Villaseca; Patricia Garcia; Juan Carlos Roa
Journal:  Virchows Arch       Date:  2014-05-21       Impact factor: 4.064

4.  mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

Authors:  Marco Giovannini; Nicolas-Xavier Bonne; Jeremie Vitte; Fabrice Chareyre; Karo Tanaka; Rocky Adams; Laurel M Fisher; Laurence Valeyrie-Allanore; Pierre Wolkenstein; Stephane Goutagny; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2014-01-10       Impact factor: 12.300

5.  mTOR-rictor is the Ser473 kinase for AKT1 in mouse one-cell stage embryos.

Authors:  Zhe Zhang; Guojun Zhang; Xiaoyan Xu; Wenhui Su; Bingzhi Yu
Journal:  Mol Cell Biochem       Date:  2011-11-05       Impact factor: 3.396

Review 6.  Targeting the bone marrow in Waldenstrom macroglobulinemia.

Authors:  Irene M Ghobrial; Yong Zhang; Yang Liu; Hai Ngo; Feda Azab; Antonio Sacco; Abdelkareem Azab; Patricia Maiso; Brittany Morgan; Phong Quang; Ghayas C Issa; Xavier Leleu; Aldo M Roccaro
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-30

7.  Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Emanuel N Husu; Costas Pitsillides; Steven Vesole; Abdel Kareem Azab; Feda Azab; Molly Melhem; Hai T Ngo; Phong Quang; Patricia Maiso; Judith Runnels; Mei-Chih Liang; Kwok-Kin Wong; Charles Lin; Irene M Ghobrial
Journal:  Blood       Date:  2009-11-19       Impact factor: 22.113

8.  Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs.

Authors:  Brian C Wulff; Jennifer M Thomas-Ahner; Jonathan S Schick; Tatiana M Oberyszyn
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

9.  Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα).

Authors:  Han C Dan; Aaron Ebbs; Manolis Pasparakis; Terry Van Dyke; Daniela S Basseres; Albert S Baldwin
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

10.  Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.

Authors:  Todd W Miller; James T Forbes; Chirayu Shah; Shelby K Wyatt; H Charles Manning; Maria G Olivares; Violeta Sanchez; Teresa C Dugger; Nara de Matos Granja; Archana Narasanna; Rebecca S Cook; J Phillip Kennedy; Craig W Lindsley; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.